Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis-Reference-Cited by-同舟云学术

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis

Published:2016-03 Issue:4 Volume:22 Page:514-520
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Valentino L. A.¹,Pipe S. W.²,Collins P. W.³,Blanchette V. S.⁴,Berntorp E.⁵,Fischer K.⁶,Ewenstein B. M.⁷,Oh M.⁷,Spotts G.⁷

Affiliation:

1. Baxalta US Inc. Deerfield ILUSA

2. University of Michigan Ann Arbor MI USA

3. School of Medicine Cardiff University Cardiff UK

4. Hospital for Sick Children Toronto ON Canada

5. Lund University Skane University Hospital Malmö Sweden

6. Van Creveldkliniek University Medical Center Utrecht Utrecht the Netherlands

7. Baxter Healthcare Corporation Westlake Village CA USA

Funder

Baxalta US, Inc.

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12905

Reference26 articles.

1. Guidelines for the management of hemophilia

2. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179.MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available athttp://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed November 4 2007.

3. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs

4. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

5. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert United Kingdom consensus on the preservation of joint health in people with moderate and severe haemophilia A: A modified Delphi panel;Haemophilia;2024-01-19

2. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A;Blood Advances;2023-11-29

3. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review;Haemophilia;2023-09-27

4. Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy;Current Gene Therapy;2023-04

5. Considerations for shared decision management in previously untreated patients with hemophilia A or B;Therapeutic Advances in Hematology;2023-01